WilmerHale Counsels Syros Pharmaceuticals in $35M Private Placement

WilmerHale Counsels Syros Pharmaceuticals in $35M Private Placement

Firm News

Syros Pharmaceuticals, a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of disease-driving genes, announced that it has entered into a stock purchase agreement with several institutional accredited investors for the private placement of 2,592,591 shares of common stock at a purchase price of $13.50 per share, yielding expected gross proceeds of $35 million.

The WilmerHale team counseling Syros included Steven Singer, Cynthia Mazareas, Mhairi Immermann, and Killian Nolan.

Read Syros Pharmaceuticals' press release for more information.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.